+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying the effectiveness, safety, and tolerability of combining elecoglipron and dapagliflozin compared to using each drug alone in adults with type 2 diabetes mellitus T2DM who are not well controlled by lifestyle changes or other diabetes medications. This phase III trial aims to understand how well these treatments manage blood sugar levels in this population. Participants will be randomly assigned to one of five groups two different doses of elecoglipron combined with dapagliflozin, two doses of elecoglipron combined with a placebo matching dapagliflozin, or dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The study uses a double-blind, parallel-group design to compare these treatments over 40 weeks. During the study, participants will have their blood sugar control measured primarily by changes in Hemoglobin A1c HbA1c from the start to week 40. Secondary measures include body weight changes, fasting plasma glucose, blood pressure, and time to starting rescue medication. Regular assessments will monitor safety and treatment effects throughout the trial period, which lasts about 40 weeks.

Age: 18Years +All GendersPhase 3
303 locations
C

Actively Recruiting

This clinical trial is studying adults who have experienced a small ischemic stroke, also known as lacunar stroke. It aims to determine if a combination of antiplatelet drugs dual antiplatelet therapy works as well as the standard treatment with intravenous tissue plasminogen activator rt-PA. Researchers also want to see if the combination reduces bleeding complications compared to rt-PA. Participants will be randomly assigned to receive either the dual antiplatelet therapy, which includes aspirin 200 mg and clopidogrel 300 mg, or intravenous rt-PA at a low dose of 0.6 mgkg alteplase, which is approved in Japan. The study follows a parallel design and is conducted at multiple centers. Treatment is given during the hyperacute phase within 4.5 hours of stroke onset. During the study, participants will be monitored for neurological status at 3 months after stroke through in-person visits, phone calls, or mail. Researchers will measure outcomes such as excellent recovery at 3 months, infarct growth, early neurological changes, stroke recurrence, and cost effectiveness. The total study period extends through March 2029, with primary outcome assessment at 3 months post-stroke.

Age: 18Years +All GendersPhase 4
29 locations
P

Actively Recruiting

Researchers are evaluating whether pemafibrate can help prevent worsening of intracranial arterial stenosis ICAS in people who have symptomatic ICAS and high triglyceride levels after an ischemic stroke or transient ischemic attack TIA. This open-label, randomized, parallel-group trial compares a group receiving pemafibrate with a group not receiving it, while all participants continue standard stroke care including antithrombotic therapy and management of vascular risk factors. The study is sponsored by Tokyo Womens Medical University. Participants assigned to the pemafibrate group will take the drug for 12 months, with possible dose adjustments based on triglyceride levels and kidney function. Both groups will receive standard medical therapy. Brain CT angiography CTA will be performed at the start and after 12 months. Additional assessments include brain MRIMRA and vascular tests such as ankle brachial index, cardio ankle vascular index, and pulse wave velocity, conducted according to the study schedule. During the study, participants will have blood tests and clinical assessments at baseline and follow-up visits. Researchers will monitor vascular events, functional outcomes, and adverse events over 12 months. The main outcome measured is progression of intracranial arterial stenosis on CTA at 12 months. Secondary outcomes include changes in stenosis severity, cardiovascular events, mortality, daily living activities, brain imaging markers, vascular indices, blood biomarkers, and safety measures throughout the treatment period.

Age: 18Years +All GendersPhase Not Applicable
42 locations